Fast Track Designation Stocks
Biotechnology firms in this cohort possess investigational drugs granted an expedited review pathway by regulatory bodies to address unmet medical needs for serious or life-threatening conditions. This designation allows for more frequent communication with regulators and eligibility for priority review, significantly reducing the time-to-market for novel therapeutics.
As of Oct 23, 2026, Fast Track Designation has 24 US-listed companies worth $21.8B combined. The median member moved -0.4% over the past week; NTHI led at +21.1% and ATHE trailed at -20.2%.
Companies in Fast Track Designation
- PCVX – Vaxcyte Inc, $9.9B
- KYMR – Kymera Therapeutics Inc, $9.3B
- OLMA – Olema Pharmaceuticals Inc, $684M
- ENTA – Enanta Pharmaceuticals Inc, $352M
- ARTV – Artiva Biotherapeutics, Inc. Common Stock, $332M
- PYXS – Pyxis Oncology Inc, $220M
- IVVD – Invivyd Inc., $182M
- TARA – Protara Therapeutics Inc, $137M
- NRXP – NRX Pharmaceuticals Inc, $113M
- PYPD – PolyPid, $103M
- ACRV – Acrivon Therapeutics, Inc. Common Stock, $81.8M
- NTHI – NeOnc Technologies Holdings, Inc. Common Stock, $79.2M
- OKYO – OKYO Pharma Limited, $77.1M
- ONCY – Oncolytics Biotech Inc, $71.8M
- ATHE – Alterity Therapeutics Ltd, $66.8M
- CRBU – Caribou Biosciences Inc, $50.4M
- DWTX – Dogwood Therapeutics, Inc., $42.5M
- MCRB – Seres Therapeutics Inc, $29.5M
- SCLX – Scilex Holding Company, $19.9M
- ALLR – Allarity Therapeutics Inc, $13.9M
- CLRB – Cellectar Biosciences Inc, $13.1M
- LGVN – Longeveron LLC, $5.1M
- GNPX – Genprex Inc, $1.7M
- BDRX – Biodexa Pharmaceticals, $860,974